The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tracking the FDA precision oncology drug approval landscape in OncoKB.
 
Sarah Phillips Suehnholz
No Relationships to Disclose
 
Ritika Kundra
No Relationships to Disclose
 
Hongxin Zhang
No Relationships to Disclose
 
Moriah H Nissan
No Relationships to Disclose
 
Calvin Lu
No Relationships to Disclose
 
Amanda Dhaneshwar
No Relationships to Disclose
 
Nicole Fernandez
No Relationships to Disclose
 
Subhiksha Nandakumar
No Relationships to Disclose
 
Maria E. Arcila
Leadership - Association for Molecular Pathology
Consulting or Advisory Role - Biocartis; PER Events, LLC
 
Marc Ladanyi
Stock and Other Ownership Interests - PAIGE.AI
Consulting or Advisory Role - ADC Therapeutics; Bayer Health; Bayer Health; MSD
Research Funding - ADC Therapeutics (Inst); Elevation Oncology (Inst); Helsinn Therapeutics (Inst); Merus NV (Inst); Rain Therapeutics
Patents, Royalties, Other Intellectual Property - Royalties from a license agreement between MSK and Sophia Genetics
 
Michael F. Berger
Honoraria - SOPHiA Genetics
Consulting or Advisory Role - AstraZeneca; PAIGE.AI
Research Funding - Boundless Bio
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
Aijazuddin Syed
No Relationships to Disclose
 
Angela Rose Brannon
Stock and Other Ownership Interests - Johnson & Johnson
Patents, Royalties, Other Intellectual Property - Intellectual Property Rights (SOPHiA Genetics)
 
Ross L. Levine
Leadership - Qiagen
Stock and Other Ownership Interests - Ajax; Anovia; Auron Therapeutics; BAKX Therapeutics; C4 Therapeutics; Epiphanes; Imago Pharma; IsoPlexis; Kurome Therapeutics; Loxo; Mana Therapeutics; Mission Bio; Prelude Therapeutics; Qiagen; Scorpion Therapeutics; Syndax; Zentalis
Honoraria - Amgen; Celgene; Genome Canada; Gilead Sciences; Incyte; Janssen; Lilly; The Mark Foundation For Cancer Research
Consulting or Advisory Role - BMS; Bridge Medicines; Bridge Therapeutics; Bridgebio; C4 Therapeutics; Celgene; Daiichi; Imago Pharma; IsoPlexis; Jubilant Biosys; Loxo; MorphoSys; Novartis; Prelude Therapeutics; Roche; Stelexis Therapeutics; Vida Ventures
Speakers' Bureau - Amgen; Lilly
Research Funding - Celgene; Cure Breast Cancer Foundation; ECOG-ACRIN; Prelude Therapeutics; Roche; The Mark Foundation For Cancer Research
Travel, Accommodations, Expenses - Auron Therapeutics; C4 Therapeutics; Constellation Pharmaceuticals; Genome Canada; Incyte; Qiagen
 
Ahmet Dogan
Consulting or Advisory Role - Incyte
 
Alexander E. Drilon
Stock and Other Ownership Interests - mBrace; Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EcoR1 Capital; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Osimertinib Selpercatinib; Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
David B. Solit
Stock and Other Ownership Interests - Elsie Biotechnologies; Fore Biotherapeutics; Function Oncology; Pyramid Biosciences; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Elsie Biotechnologies; Fog Therapeutics; Fore Biotherapeutics; Function Oncology; PAIGE.AI (I); Pfizer; Pyramid Biosciences; Rain Therapeutics; Scorpion Therapeutics; Vividion Therapeutics
 
Nikolaus Schultz
Honoraria - OneOncology
 
Debyani Chakravarty
Consulting or Advisory Role - Medendi Medical Travel